Stracher AR, Stoeckle MY, Giordano HF "Aplastic anemia during malarial prophylaxis with mefloquine." Bull World Health Organ 61 (1983): 809-1435. Abstract. Concise summaries and expert physician commentary that busy clinicians need to enhance patient care.The most effective and engaging way for clinicians to learn, improve their practice, and prepare for board exams.NEW! All rights reserved. Fonteyne W, Bauwens A, Jordaens L "Atrial flutter with 1:1 conduction after administration of the antimalarial drug mefloquine." Its report, Effects of Mefloquine Use Among Canadian Veterans, concluded that “the current state of research does not establish a conclusive link” between permanent neuropsychiatric effects and mefloquine use. Mefloquine should not be prescribed for prophylaxis in patients with major psychiatric disorders. Ann Intern Med 123 (1995): 89453. VAGUE NUMBERS The medical community may be slow to acknowledge mefloquine concerns because no one knows how many users experience chronic neuropsychiatric side effects. Am J Trop Med Hyg 45 (1991): 86-9113. Clin Cardiol 19 (1996): 967-847. Cerner Multum, Inc. "UK Summary of Product Characteristics."

Can J Psychiatry 41 (1996): 19623. The drug was licensed by the FDA in 1989 after development by scientists affiliated with Walter Reed Army Institute of Research (WRAIR). N Engl J Med 359 (2008): 603-1226. Scerri L, Pace JL "Mefloquine-associated cutaneous vasculitis." The incidence of these side effects is 1 in 13,000 with prophylactic use and 1 in 250 with therapeutic use.The first randomized, controlled trial on a mixed population was performed in 2001. Lancet 2 (1989): 8656. Mefloquine hydrochloride is now one of the major antimalarial drugs used both in prophylactic and therapeutic regimens.

Eur J Clin Pharmacol 58 (2002): 441-512. J R Coll Physicians Lond 32 (1998): 203-77.

You may report them to the The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. White NJ "Mefloquine."

In Meyler's Side Effects of Drugs (Sixteenth Edition), 2016. M efloquine is an antimalarial drug that is associated with a significant risk of chronic neuropsychiatric adverse effects (AEs). Cerner Multum, Inc. "Australian Product Information." These side effects may go away during treatment as your body adjusts to the medicine. Lancet 341 (1993): 63239. Lancet 347 (1996): 3269. Its elimination in persons with impaired liver function may be prolonged, resulting in higher plasma levels and an increased risk of adverse reactions. Mefloquine may cause neuropsychiatric adverse reactions that can persist after mefloquine has been discontinued.

Ruff TA, Sherwen SJ, Donnan GA "Seizure associated with mefloquine for malaria prophylaxis." -Splitting the total dose into 2 doses given 6 to 8 hours apart may reduce the occurrence/severity of side effects. J Trop Med Hyg 95 (1992): 167-7928. Common side effects include vomiting, diarrhea, headaches, sleep disorders, and a rash.Mefloquine was developed by the United States Army in the 1970s and came into use in the mid 1980s.Mefloquine is used to both prevent and treat certain forms of malaria.Mefloquine is useful for the prevention of malaria in all areas except for those where parasites may have Common side effects include vomiting, diarrhea, headaches, and a rash.Central nervous system events requiring hospitalization occur in about one in 10,000 people taking mefloquine for malaria prevention, with milder events (e.g., dizziness, headache, Mefloquine may cause abnormalities with heart rhythms that are visible on Mefloquine is contraindicated in those with a previous history of seizures or a recent history of psychiatric disorders.Available data suggests that mefloquine is safe and effective for use by pregnant women during all trimesters of pregnancy,Mefloquine is also safe and effective for use during breastfeeding,Mefloquine is metabolized primarily through the liver. Alcohol. Van Den Eden E, Van Gompel A, Colebunders R, Van Den Ende J "Mefloquine-induced Stevens-Johnson syndrome."